FDA says ‘no clinical need’ for compounded weight loss drugs

The U.S. Meals and Drug Administration has proposed excluding the energetic components in wildly standard weight problems and diabetes medication from an inventory of gear that can be utilized for guaranteeing compounded variations.

The company decided there isn’t a “scientific want” to permit giant compounding amenities to make giant portions of medicines from semaglutide, the ingredient in Novo Nordisk’s Wegovy weight-loss and Ozempic diabetes remedies, in addition to tirzepatide, the ingredient in Eli Lilly’s Moujaro diabetes drug and Zepbound weight problems medication.

The choice singled out these compounders, that are often known as 503B amenities in regulatory parlance, after rising controversy over their function in making weight-loss remedies obtainable over the previous few years. In explaining its resolution — which is a victory for Novo and Lilly and rework decisions for customers — the FDA defined these compounders not meet the authorized necessities to market their merchandise.